Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
- Conditions
- Hairy Cell LeukemiaSecondary Acute Myeloid LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeNeoplasm of Uncertain Malignant PotentialChronic Lymphocytic LeukemiaAcute Undifferentiated LeukemiaChildhood Acute Lymphoblastic LeukemiaChildhood Acute Myeloid LeukemiaChildhood Solid NeoplasmJuvenile Myelomonocytic Leukemia
- Registration Number
- NCT00898079
- Lead Sponsor
- Children's Oncology Group
- Brief Summary
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Detailed Description
OBJECTIVES:
I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol.
II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients.
III. Make specimens available to qualified researchers to understand the biology of cancer in these patients.
OUTLINE:
Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2545
-
Meets any of the following criteria:
- Diagnosed with primary neoplasm
- Developed a second malignant neoplasm
- Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
-
Must have biological specimens including solid tumors and leukemias available
-
Solid tumors meeting the following criteria:
-
Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)
- Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
-
-
Pleural fluid or cytologic specimens meeting the following criteria:
-
At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)
- Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
-
-
ALL/AML
- 3-6 mL of bone marrow aspirate and 10 mL of whole blood
-
-
Not eligible for disease-specific biology or banking protocol
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Repository of malignant, borderline malignant neoplasms, and related biological specimens Baseline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (192)
Children's Hospital of Alabama
🇺🇸Birmingham, Alabama, United States
University of Alabama at Birmingham Cancer Center
🇺🇸Birmingham, Alabama, United States
Phoenix Childrens Hospital
🇺🇸Phoenix, Arizona, United States
Arkansas Children's Hospital
🇺🇸Little Rock, Arkansas, United States
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center
🇺🇸Downey, California, United States
City of Hope Comprehensive Cancer Center
🇺🇸Duarte, California, United States
Loma Linda University Medical Center
🇺🇸Loma Linda, California, United States
Miller Children's and Women's Hospital Long Beach
🇺🇸Long Beach, California, United States
Children's Hospital Los Angeles
🇺🇸Los Angeles, California, United States
Scroll for more (182 remaining)Children's Hospital of Alabama🇺🇸Birmingham, Alabama, United States